AOTMiT: Transparency Council on optometrist's advice, drug-resistant epilepsy and lymphoma, among others

Agenda

A. Guaranteed benefits

Preparation of a position on the qualification of the health care service "Optometrist's advice "as a guaranteed benefit.

B. Health technology assessment (drugs)

1. Legrex (ticagrelorum) - in combination with ASA for the prevention of cardiovascular events in adult patients with a history of myocardial infarction and a high risk of cardiovascular events.
2. Legrex (ticagrelorum) - in combination with ASA to prevent cardiovascular events in adult patients with acute coronary syndrome (ACS).
3. Itulazax (betula verrucosa) - treatment of allergic rhinitis and/or conjunctivitis, caused by the birch allergen homolog family, in children and adolescents aged 5-17 years (diagnosis: clinical history and positive allergy test to the birch homolog family: spot skin tests and/or specific IgE).
4. CRYSVITA (burosumabum) - under drug program B.151. "Treatment of patients with X-linked hypophosphatemia".
5. Columvi (glofitamabum) - within the framework of the drug program B.12.FM. "Treatment of patients with B-cell lymphomas (ICD-10: C82, C83, C85)".

C. Reasonableness of reimbursement approvals

1. Ospolot (sultiamum) - indications:
   - epilepsy, drug-resistant epilepsy,
   - drug-resistant epilepsy in the course of Rett syndrome.
2. Inovelon (rufinamidum) - indications:
   - drug-resistant epilepsy,
   - Lennox-Gastaut syndrome.
3. Fycompa (perampanelum) - indications:
   - drug-resistant epilepsy,
   - drug-resistant epilepsy with focal seizures.

Source: AOTMiT